Location-based prediction model for Crohn’s disease regarding a novel serological marker, anti-chitinase 3-like 1 autoantibodies

Table 2 Prevalence of autoantibodies against chitinase 3-like 1 in inflammatory bowel disease patients

Serum aCHI3L1	CD (n = 257)		UC (n = 180)		HCONT (n = 86)
	n	%	n	%	n	%
IgG	21	8.2%b	3	1.7%b	2	2.83%
IgA	75	29.2%a,c	20	11.1%c,d	2	2.83%a,d
sIgA	101	39.3%a	59	32.8%e	4	4.65%a,e

^aP ≤ 0.0001. Crohn’s disease vs controls.

^bP = 0.003. Crohn’s disease vs ulcerative colitis.

^cP ≤ 0.0001. Crohn’s disease vs ulcerative colitis.

^dP = 0.016. Ulcerative colitis vs controls.

^eP ≤ 0.0001. Ulcerative colitis vs controls.

Using χ²-test with Yates correction. CD: Crohn’s disease; UC: Ulcerative colitis; IgA: Immunoglobulin A; sIgA: Secretory immunoglobulin A; aCHI3L1: Anti-chitinase 3-like 1 autoantibodies; HCONT: Healthy controls.